Mural Oncology (NASDAQ:MURA) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Mural Oncology (NASDAQ:MURA) in a research report report published on Monday morning,Benzinga reports. They currently have a $18.00 target price on the stock.

Separately, Raymond James initiated coverage on Mural Oncology in a research report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 price target on the stock.

Mural Oncology Price Performance

NASDAQ:MURA opened at $3.52 on Monday. The company’s 50 day moving average is $3.38 and its 200-day moving average is $3.38. Mural Oncology has a 12 month low of $2.88 and a 12 month high of $17.00. The firm has a market cap of $59.98 million and a price-to-earnings ratio of -0.34.

Mural Oncology (NASDAQ:MURA) last announced its earnings results on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, topping the consensus estimate of ($1.90) by $0.04. Research analysts predict that Mural Oncology will post -7.59 EPS for the current fiscal year.

Insider Transactions at Mural Oncology

In related news, CFO Adam D. Cutler sold 7,421 shares of the stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $3.41, for a total value of $25,305.61. Following the completion of the sale, the chief financial officer now owns 71,438 shares in the company, valued at approximately $243,603.58. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Mural Oncology

Several institutional investors and hedge funds have recently bought and sold shares of MURA. FMR LLC lifted its holdings in shares of Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after acquiring an additional 11,423 shares during the period. Commerce Bank bought a new position in Mural Oncology during the third quarter worth about $39,000. Cubist Systematic Strategies LLC acquired a new stake in Mural Oncology during the second quarter valued at approximately $98,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Mural Oncology in the 2nd quarter valued at approximately $84,000. Finally, Armistice Capital LLC acquired a new position in shares of Mural Oncology in the 2nd quarter worth approximately $5,300,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.